Inhibition of human diffuse large B-cell lymphoma growth by JC polyomavirus-like particles delivering a suicide gene

详细信息    查看全文

• 作者：Chun-Nun Chao (1) (2)
  Yih-Leh Huang (3)
  Mien-Chun Lin (1) (4)
  Chiung-Yao Fang (5)
  Cheng-Huang Shen (4)
  Pei-Lain Chen (6)
  Meilin Wang (7)
  Deching Chang (1)
  Chih-En Tseng (8) (9)
  
  1. Institute of Molecular Biology ; National Chung Cheng University ; Chiayi ; Taiwan
  2. Department of Pediatrics ; Chiayi Christian Hospital ; Chiayi ; Taiwan
  3. Department of Medical Research ; Buddhist Dalin Tzu Chi General Hospital ; Chiayi ; Taiwan
  4. Department of Urology ; Chiayi Christian Hospital ; Chiayi ; Taiwan
  5. Department of Medical Research ; Chiayi Christian Hospital ; Chiayi ; Taiwan
  6. Department of Medical Laboratory Science and Biotechnology ; Central Taiwan University of Science and Technology ; Taichung ; Taiwan
  7. Department of Microbiology and Immunology ; Chung Shan Medical University ; Taichung ; Taiwan
  8. Department of Anatomic Pathology ; Buddhist Dalin Tzu Chi General Hospital ; Chiayi ; Taiwan
  9. School of Medicine ; Tzu Chi University ; Hualien ; Taiwan
  
• 关键词：Diffuse large B ; cell lymphoma ; Gene therapy ; JCPyV VLPs ; Suicide gene ; HSV ; TK/GCV
• 刊名：Journal of Translational Medicine
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：13
• 期：1
• 全文大小：1,554 KB
• 参考文献：1. Project TN-HsLC. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin鈥檚 lymphoma. The Non-Hodgkin鈥檚 Lymphoma Classification Project. Blood. 1997;89:3909鈥?8.
  2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503鈥?1. CrossRef
  3. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937鈥?7. CrossRef
  4. Fisher RI. CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphoma. Important Adv Oncol 1990;217鈥?25.
  5. Czuczman MS, Leonard JP, Williams ME. Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion. Clin Adv Hematol Oncol. 2010;8:A1鈥?4. quiz A15.
  6. Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:498鈥?05. CrossRef
  7. Verma IM, Weitzman MD. Gene therapy: twenty-first century medicine. Annu Rev Biochem. 2005;74:711鈥?8. CrossRef
  8. Lee JM, Yoon TJ, Cho YS. Recent developments in nanoparticle-based siRNA delivery for cancer therapy. Biomed Res Int. 2013;2013:782041.
  9. Awada A, Aftimos PG. Targeted therapies of solid cancers: new options, new challenges. Curr Opin Oncol. 2013;25:296鈥?04.
  10. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985;228:1440鈥?. CrossRef
  11. Weiss LM, Warnke RA, Sklar J, Cleary ML. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med. 1987;317:1185鈥?. CrossRef
  12. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A. 1982;79:7824鈥?. CrossRef
  13. Moreira JN, Santos A, Simoes S. Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality. Rev Recent Clin Trials. 2006;1:217鈥?5. CrossRef
  14. Buttgereit P, Schmidt-Wolf IG. Gene therapy of lymphoma. J Hematother Stem Cell Res. 2002;11:457鈥?7. CrossRef
  15. Pistoia V, Cocco C, Airoldi I. Interleukin-12 receptor beta2: from cytokine receptor to gatekeeper gene in human B-cell malignancies. J Clin Oncol. 2009;27:4809鈥?6. CrossRef
  16. Takahashi S, Yotnda P, Rousseau RF, Mei Z, Smith S, Rill D, et al. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin鈥檚 lymphoma. Cancer Gene Ther. 2001;8:378鈥?7. CrossRef
  17. Misumi M, Suzuki T, Moriuchi S, Glorioso JC, Bessho M. In vitro thymidine kinase/ganciclovir-based suicide gene therapy using replication defective herpes simplex virus-1 against leukemic B-cell malignancies (MCL, HCL, B-CLL). Leuk Res. 2003;27:695鈥?. CrossRef
  18. Alain T, Thirukkumaran C, Morris DG, Urbanski SJ, Janowska-Wieczorek A, Lee PW, et al. Lymphomas and oncolytic virus therapy. Clin Lymphoma. 2003;4:104鈥?1. CrossRef
  19. Goldmann C, Petry H, Frye S, Ast O, Ebitsch S, Jentsch KD, et al. Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies. J Virol. 1999;73:4465鈥?.
  20. Hale AD, Bartkeviciute D, Dargeviciute A, Jin L, Knowles W, Staniulis J, et al. Expression and antigenic characterization of the major capsid proteins of human polyomaviruses BK and JC in Saccharomyces cerevisiae. J Virol Methods. 2002;104:93鈥?. CrossRef
  21. Fang CY, Lin PY, Ou WC, Chen PL, Shen CH, Chang D, et al. Analysis of the size of DNA packaged by the human JC virus-like particle. J Virol Methods. 2012;182:87鈥?2. CrossRef
  22. Teunissen EA, de Raad M, Mastrobattista E. Production and biomedical applications of virus-like particles derived from polyomaviruses. J Control Release. 2013;172:305鈥?1. CrossRef
  23. Dorries K, Vogel E, Gunther S, Czub S. Infection of human polyomaviruses JC and BK in peripheral blood leukocytes from immunocompetent individuals. Virology. 1994;198:59鈥?0. CrossRef
  24. Atwood WJ, Amemiya K, Traub R, Harms J, Major EO. Interaction of the human polyomavirus, JCV, with human B-lymphocytes. Virology. 1992;190:716鈥?3. CrossRef
  25. Ou WC, Wang M, Fung CY, Tsai RT, Chao PC, Hseu TH, et al. The major capsid protein, VP1, of human JC virus expressed in Escherichia coli is able to self-assemble into a capsid-like particle and deliver exogenous DNA into human kidney cells. J Gen Virol. 1999;80(Pt 1):39鈥?6.
  26. Chen PL, Wang M, Ou WC, Lii CK, Chen LS, Chang D. Disulfide bonds stabilize JC virus capsid-like structure by protecting calcium ions from chelation. FEBS Lett. 2001;500:109鈥?3. CrossRef
  27. Chang D, Fung CY, Ou WC, Chao PC, Li SY, Wang M, et al. Self-assembly of the JC virus major capsid protein, VP1, expressed in insect cells. J Gen Virol. 1997;78(Pt 6):1435鈥?.
  28. Ou WC, Hseu TH, Wang M, Chang H, Chang D. Identification of a DNA encapsidation sequence for human polyomavirus pseudovirion formation. J Med Virol. 2001;64:366鈥?3. CrossRef
  29. Chen LS, Wang M, Ou WC, Fung CY, Chen PL, Chang CF, et al. Efficient gene transfer using the human JC virus-like particle that inhibits human colon adenocarcinoma growth in a nude mouse model. Gene Ther. 2010;17:1033鈥?1. CrossRef
  30. Tseng CE, Yeh CM, Fang CY, Shay J, Chen PL, Lin MC, et al. Detection of human JCPyV and BKPyV in diffuse large B-cell lymphoma of the GI tract. Eur J Clin Microbiol Infect Dis. 2014;33:665鈥?2. CrossRef
  31. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin鈥檚 lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin鈥檚 Lymphoma Classification Project. J Clin Oncol. 1998;16:2780鈥?5.
  32. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin鈥檚 lymphoma. N Engl J Med. 1995;333:1540鈥?. CrossRef
  33. Houldsworth J, Petlakh M, Olshen AB, Chaganti RS. Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response. Leuk Lymphoma. 2008;49:2170鈥?0. CrossRef
  34. Navaratnam S, Williams GJ, Rubinger M, Pettigrew NM, Mowat MR, Begleiter A, et al. Expression of p53 predicts treatment failure in aggressive non-Hodgkin鈥檚 lymphomas. Leuk Lymphoma. 1998;29:139鈥?4. CrossRef
  35. Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin鈥檚 lymphomas. Blood. 1997;89:601鈥?.
  36. Kawauchi K, Ogasawara T, Yasuyama M, Otsuka K, Yamada O. The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem. 2009;9:550鈥?. CrossRef
  37. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129:1261鈥?4. CrossRef
  38. Baohua Y, Xiaoyan Z, Tiecheng Z, Tao Q, Daren S. Mutations of the PIK3CA gene in diffuse large B cell lymphoma. Diagn Mol Pathol. 2008;17:159鈥?5. CrossRef
  39. Hasselblom S, Hansson U, Olsson M, Toren L, Bergstrom A, Nilsson-Ehle H, et al. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Br J Haematol. 2010;149:560鈥?. CrossRef
  40. Uddin S, Bu R, Ahmed M, Hussain AR, Ajarim D, Al-Dayel F, et al. Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma. Leuk Lymphoma. 2010;51:1305鈥?4. CrossRef
  41. Schatz JH. Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin鈥檚 lymphoma: results, biology, and development strategies. Curr Oncol Rep. 2011;13:398鈥?06. CrossRef
  42. Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011;25:341鈥?. CrossRef
  43. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002;108:153鈥?4. CrossRef
  44. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol. 1994;124:1鈥?. CrossRef
  45. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood. 1996;88:386鈥?01.
  46. Fukuhara S, Rowley JD, Variakojis D, Golomb HM. Chromosome abnormalities in poorly differentiated lymphocytic lymphoma. Cancer Res. 1979;39:3119鈥?8.
  47. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin鈥檚 lymphoma. Blood. 1997;90:244鈥?1.
  48. Sanchez E, Chacon I, Plaza MM, Munoz E, Cruz MA, Martinez B, et al. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol. 1998;16:1931鈥?.
  49. Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, et al. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol. 2008;143:355鈥?0. CrossRef
  50. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 1997;13:513鈥?09. CrossRef
  51. Monroe JG. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol. 2006;6:283鈥?4. CrossRef
  52. Hollmann CA, Tzankov A, Martinez-Marignac VL, Baker K, Grygorczyk C, Grygorczyk R, et al. Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma. Leuk Res. 2010;34:585鈥?3. CrossRef
  53. Maxwell SA, Mousavi-Fard S. Non-Hodgkin鈥檚 B-cell lymphoma: advances in molecular strategies targeting drug resistance. Exp Biol Med (Maywood). 2013;238:971鈥?0. CrossRef
  54. Lin MC, Wang M, Fang CY, Chen PL, Shen CH, Chang D. Inhibition of BK virus replication in human kidney cells by BK virus large tumor antigen-specific shRNA delivered by JC virus-like particles. Antiviral Res. 2014;103:25鈥?1. CrossRef
  55. Goldmann C, Stolte N, Nisslein T, Hunsmann G, Luke W, Petry H. Packaging of small molecules into VP1-virus-like particles of the human polyomavirus JC virus. J Virol Methods. 2000;90:85鈥?0. CrossRef
  56. Wang M, Tsou TH, Chen LS, Ou WC, Chen PL, Chang CF, et al. Inhibition of simian virus 40 large tumor antigen expression in human fetal glial cells by an antisense oligodeoxynucleotide delivered by the JC virus-like particle. Hum Gene Ther. 2004;15:1077鈥?0. CrossRef
  57. Duarte S, Carle G, Faneca H, de Lima MC, Pierrefite-Carle V. Suicide gene therapy in cancer: where do we stand now? Cancer Lett. 2012;324:160鈥?0. CrossRef
  58. Fillat C, Carrio M, Cascante A, Sangro B. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther. 2003;3:13鈥?6. CrossRef
  59. Altanerova V, Cihova M, Babic M, Rychly B, Ondicova K, Mravec B, et al. Human adipose tissue-derived mesenchymal stem cells expressing yeast cytosinedeaminase::uracil phosphoribosyltransferase inhibit intracerebral rat glioblastoma. Int J Cancer. 2012;130:2455鈥?3. CrossRef
  60. Zhou JH, Tang B, Liu XL, He DW, Yang DT. hTERT-targeted E. coli purine nucleoside phosphorylase gene/6-methylpurine deoxyribose therapy for pancreatic cancer. Chin Med J (Engl). 2007;120:1348鈥?2.
  61. Patel P, Young JG, Mautner V, Ashdown D, Bonney S, Pineda RG, et al. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. Mol Ther. 2009;17:1292鈥?. CrossRef
  62. Girald W, Collin A, Izquierdo M. Toxicity and delivery methods for the linamarase/linamarin/glucose oxidase system, when used against human glioma tumors implanted in the brain of nude rats. Cancer Lett. 2011;313:99鈥?07. CrossRef
  63. Lupo-Stanghellini MT, Provasi E, Bondanza A, Ciceri F, Bordignon C, Bonini C. Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. Hum Gene Ther. 2010;21:241鈥?0. CrossRef
  64. Balfour Jr HH. Antiviral drugs. N Engl J Med. 1999;340:1255鈥?8. CrossRef
  65. Wei SJ, Chao Y, Hung YM, Lin WC, Yang DM, Shih YL, et al. S- and G2-phase cell cycle arrests and apoptosis induced by ganciclovir in murine melanoma cells transduced with herpes simplex virus thymidine kinase. Exp Cell Res. 1998;241:66鈥?5. CrossRef
  66. Bondanza A, Hambach L, Aghai Z, Nijmeijer B, Kaneko S, Mastaglio S, et al. IL-7 receptor expression identifies suicide gene-modified allospecific CD8+ T cells capable of self-renewal and differentiation into antileukemia effectors. Blood. 2011;117:6469鈥?8. CrossRef
  67. Staquicini FI, Ozawa MG, Moya CA, Driessen WH, Barbu EM, Nishimori H, et al. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J Clin Invest. 2011;121:161鈥?3. CrossRef
  68. Tang W, He Y, Zhou S, Ma Y, Liu G. A novel Bifidobacterium infantis-mediated TK/GCV suicide gene therapy system exhibits antitumor activity in a rat model of bladder cancer. J Exp Clin Cancer Res. 2009;28:155. CrossRef
  69. Shirakawa T, Terao S, Hinata N, Tanaka K, Takenaka A, Hara I, et al. Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Hum Gene Ther. 2007;18:1225鈥?2. CrossRef
  70. Alvarez RD, Gomez-Navarro J, Wang M, Barnes MN, Strong TV, Arani RB, et al. Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther. 2000;2:524鈥?0. CrossRef
  71. Li N, Zhou J, Weng D, Zhang C, Li L, Wang B, et al. Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2007;13:5847鈥?4. CrossRef
  72. Wirth T, Samaranayake H, Pikkarainen J, Maatta AM, Yla-Herttuala S. Clinical trials for glioblastoma multiforme using adenoviral vectors. Curr Opin Mol Ther. 2009;11:485鈥?2.
  73. Chang CF, Wang M, Ou WC, Chen PL, Shen CH, Lin PY, et al. Human JC virus-like particles as a gene delivery vector. Expert Opin Biol Ther. 2011;11:1169鈥?5. CrossRef
  74. Forstova J, Krauzewicz N, Sandig V, Elliott J, Palkova Z, Strauss M, et al. Polyoma virus pseudocapsids as efficient carriers of heterologous DNA into mammalian cells. Hum Gene Ther. 1995;6:297鈥?06. CrossRef
  75. Gee GV, Tsomaia N, Mierke DF, Atwood WJ. Modeling a sialic acid binding pocket in the external loops of JC virus VP1. J Biol Chem. 2004;279:49172鈥?. CrossRef
  
• 刊物主题：Biomedicine general; Medicine/Public Health, general;
• 出版者：BioMed Central
• ISSN：1479-5876

文摘

Background Diffuse large B-cell lymphoma (DLBCL) is one of the most common types of aggressive B-cell non-Hodgkin lymphoma. About one-third of patients are either refractory to the treatment or experience relapse afterwards, pointing to the necessity of developing other effective therapies for DLBCL. Human B-lymphocytes are susceptible to JC polyomavirus (JCPyV) infection, and JCPyV virus-like particles (VLPs) can effectively deliver exogenous genes to susceptible cells for expression, suggesting the feasibility of using JCPyV VLPs as gene therapy vectors for DLBCL. Methods The JCPyV VLPs packaged with a GFP reporter gene were used to infect human DLBCL cells for gene delivery assay. Furthermore, we packaged JCPyV VLPs with a suicide gene encoding thymidine kinase (TK) to inhibit the growth of DLBCL in vitro and in vivo. Results Here, we show that JCPyV VLPs effectively entered human germinal center B-cell-like (GCB-like) DLBCL and activated B-cell-like (ABC-like) DLBCL and expressed the packaged reporter gene in vitro. As measured by the MTT assay, treatment with tk-VLPs in combination with gancyclovir (GCV) reduced the viability of DLBCL cells by 60%. In the xenograft mouse model, injection of tk-VLPs through the tail vein in combination with GCV administration resulted in a potent 80% inhibition of DLBCL tumor nodule growth. Conclusions Our results demonstrate the effectiveness of JCPyV VLPs as gene therapy vectors for human DLBCL and provide a potential new strategy for the treatment of DLBCL.